IP due diligence is a structured review of the intellectual property a company or project owns or uses. It tests who owns each asset, how strong it is, what restrictions are attached to it and whether the business can use it without infringing someone else's rights. Investors, licensees and acquirers run it before they commit money. Smart owners run it on themselves first, so they find the defects before anyone else does.
This guide explains what the review covers, which documents get examined, how to prove ownership, and what changes for startups, university spinouts and biotech companies.
TL;DR
- IP due diligence checks four things: ownership and transferability, scope, validity and enforceability, and freedom to operate.
- Expect it before a license, a venture financing, a sale or an IPO. Reviewing your own IP first lets you repair defects before a counterparty finds them.
- Ownership and freedom to operate are separate tests. Owning a patent does not mean you are free to sell the product.
- University spinouts and federally funded biotech need extra checks: institutional IP policies, Bayh-Dole obligations, sponsored research terms and materials rights.
- Findings can change price, royalties, equity, timing or whether the deal happens at all.
Table of Contents
- What IP due diligence is
- When you need it
- What gets reviewed
- How to verify ownership
- Freedom to operate is a separate question
- Startup and spinout IP due diligence
- Biotech IP due diligence
- What the findings change
- A preparation checklist
- Perspective
- Get ready before the counterparty asks
- FAQ
- Sources
What IP due diligence is
Think of it as an audit of what a company says it has. A seller, founder or licensor claims certain patents, software, data and know-how. The reviewer verifies each claim against records and contracts.
The core questions, as Finnegan's materials for the Association of Corporate Counsel group them, are:
- Freedom to operate: can the business make and sell its product without infringing third-party rights?
- Scope, validity and enforceability: do the patents and other rights actually protect what matters, and would they hold up?
- Ownership and transferability: does the party in front of you own the asset, and can the rights move to a new owner or licensee?
How deep the review goes depends on the deal and on how central the IP is to the value. A software acquisition where the code is the whole business gets a harder look at copyrights and open-source use. A drug candidate gets a hard look at patents, regulatory exclusivity and materials.
When you need it
The review is relevant before a license, a startup financing led by venture capital, a trade sale or an IPO, according to WIPO's due diligence readiness guide. In practice that means four common moments:
- You are the buyer or investor. You want to know what you are paying for.
- You are the licensee. You need to confirm the licensor can grant the rights, in your field and territory.
- You are the founder raising money. Investors will ask for your IP records, and gaps show up fast.
- You are the university or inventor. Before you license technology, a clean file speeds negotiation and protects your position.
If you are unsure whether your situation calls for it, a good rule is this: if someone is about to pay for, rely on or build a company around an asset, somebody should verify the asset first.
What gets reviewed
A reviewer works from two sources: official registers and your own documents. A typical data room, according to Cooley's U.S. preparation guide, includes:
- Lists of patents and patent applications
- Assignment documents
- Employee and independent-contractor agreements that secure proprietary information and inventions
- A list of personnel who have not signed such agreements or who have withheld rights
- Technical documentation
- Information on competitors' use of the inventions and awareness of others' patents
Beyond patents, a useful inventory also covers data, software, materials, trade secrets and know-how, as Nucleate's guide to university licensing points out. For life sciences, cell lines, antibodies, plasmids and datasets often carry as much value as the patents.
Contracts that touch your IP
Agreements matter as much as registrations. Skadden's M&A checklist lists licenses, R&D agreements, collaborations, joint ventures, consulting, manufacturing, supply, distribution and sponsorship agreements, settlements, covenants not to sue and consents to use.
For each license, the same checklist says to capture:
| Term | Why it matters |
|---|---|
| Parties and licensed IP | Confirms who can grant what |
| Field of use and territory | Limits where and how you can commercialize |
| Exclusivity | Determines whether competitors can get the same rights |
| Grantbacks and improvements | Decides who owns what you develop next |
| Royalties and milestones | Drives your cost model |
| Term and termination | Sets how long the rights last and what ends them |
| Assignment and change of control | Can block or complicate a sale or merger |
| Indemnities and governing law | Allocates risk if something goes wrong |
How to verify ownership
Ownership is the most common place for problems. The method is a chain-of-title trace.
- Start with the inventor or creator. Identify every person who contributed to each asset.
- Check the paper. Review employment agreements, consulting agreements and any third-party obligations. Finnegan recommends checking USPTO assignment records, inventor backgrounds, employment agreements and third-party obligations.
- Follow every transfer. Trace ownership through each assignment, merger or restructuring to the current entity.
- Look for encumbrances. Check state records for security interests or liens.
- Compare disclosure to registers. Confirm current ownership, active status, expiration and maintenance deadlines against independent searches.
Know the limits of searching. Skadden notes that owner searches can miss unrecorded predecessor assignments and unpublished U.S. patent applications filed less than 18 months earlier. A clean search is a good sign, not a guarantee, which is why contracts and interviews with inventors still matter.
Build an IP map before anyone asks
WIPO recommends an IP map: a table listing each asset, its inventor or creator, its current owner or licensee, every link in the chain of title and the supporting documents, including employment, collaboration, assignment, material transfer, consent and license documents. WIPO says the map both exposes defects and speeds up the counterparty's review. It is a few days of work that can save weeks in a negotiation.

Freedom to operate is a separate question
Founders often assume that a granted patent settles everything. It does not. A biotech company may own patents covering its product and still infringe a third party's patent. Venner Shipley's pocket guide notes that a proper freedom-to-operate review identifies blocking rights, the relevant jurisdictions and whether licenses or cross-licenses are needed.
Scope matters too. Finnegan's guidance says FTO should be tailored to the product, manufacturing and processes, relevant competitors, risk areas and commercial geographies, and may need to address a specific feature, device, small molecule or compound class rather than only the headline product.
We cover the method in detail in our guide to freedom to operate analysis. Treat it as its own workstream, run alongside the ownership trace.
Startup and spinout IP due diligence
Startups rarely have a long paper trail, which makes the paper trail you do have more important. Investors will look for three things: that founders and early contributors assigned their inventions to the company, that nothing is promised elsewhere, and that any university rights are clearly documented.
University-originated technology
If the technology came out of a university lab, the university may own it, whatever the founders believe. Ropes & Gray's life-sciences practitioners warn that a startup spun out by an academic investigator may not own the university's patents or data, and that negotiations must be with the actual rights owner.
Nucleate's guide advises mapping founders, faculty, staff, postdocs, students, visitors, consultants, contractors and collaborators against institutional IP policies and signed agreements. Then review invention disclosures, patent filings, contributor status and assignment documents.
If the university declines to pursue patent protection, founders may ask whether the company can take over prosecution or receive an assignment. That depends on university policy and any funding obligations, so ask early. For background on how these relationships work, see our overview of university tech transfer.
Fixing gaps before a financing
Common repairs include:
- Getting missing invention assignments signed by founders, employees and contractors
- Documenting who invented what and when
- Separating university-owned IP from IP the company developed on its own
- Negotiating a license, option or assignment with the university for the foundational technology
- Cleaning up material transfer agreements and consents
The earlier these happen, the cheaper they are. A missing signature from a departed postdoc is easy to fix this month and awkward in the middle of a term sheet.
Biotech IP due diligence
Biotech adds layers because value depends on years of protection, regulatory timing and materials that other people may control.
Patent life and market protection. Fenwick's life-sciences guidance says to examine the patent lifecycle and market protection relative to product launch and regulatory exclusivity, in-licensing terms, and rights to biological materials, including whether commercial use needs a separate license on viable financial terms. Diligence is partly a value and timing exercise: patent term, exclusivity and launch sequencing decide how much practical protection remains.
Federal funding and Bayh-Dole. For federally funded U.S. research, you must check Bayh-Dole obligations. Penn State's inventor guide explains that qualifying universities and nonprofits keep ownership only while meeting obligations such as protection, commercialization, agency reporting and inventor revenue sharing. The COGR guide to the Act states that universities must give the government a confirmatory license and comply with reporting, patent-notice and utilization requirements. Government-funded research can leave the government a paid-up, nonexclusive license and other statutory rights.
Practically, map each invention to its funding source and confirm that invention reports, title elections, filing deadlines and government-support statements were handled. Keeping privately developed background IP separate from federally funded work also limits uncertainty about government rights.
Collaborations and sponsored research. Venable's life-sciences materials list R&D agreements, material transfer agreements, funding arrangements, government and university sponsorship agreements, licenses, audits and employment agreements as relevant records. Look at data ownership, publication rights, ownership of improvements and flow-down provisions.
Field and scope fit. A signed license is not enough. The commercial team should test whether the license's field and scope match the intended development path. A license limited to one indication is a problem if your lead plan is another.
If you are mapping the route from lab to market, our guide to life science commercialization puts the IP questions in context with development and regulatory steps.

What the findings change
Diligence is not pass or fail. Findings reshape the deal. WIPO identifies downward renegotiation, delay, extra negotiations and abandonment as consequences of defects. Reviewers can respond by adjusting price, royalties, equity, representations, indemnities, escrow, timing or deal structure.
Licenses deserve a note. A university license generally grants defined rights rather than transferring ownership. Case Western Reserve's guidebook describes licenses that may be exclusive or nonexclusive and limited by field, territory and term, with diligence obligations and financial payments. When you read a license, read the obligations as carefully as the grant.
The seller-side lesson is clear. WIPO recommends diligence before a deal because early remediation preserves negotiating leverage and lowers the chance of delay, repricing or abandonment.
A preparation checklist
Use this list to get ready before an investor, licensee or acquirer asks.
- Build the IP map: every asset, inventor, owner, chain-of-title link and supporting document.
- Collect signed invention assignment and confidentiality agreements from every employee, contractor and collaborator.
- Pull all licenses, MTAs, sponsored research and collaboration agreements into one folder.
- List every funding source and tie each invention to it.
- Confirm maintenance fees and deadlines for each patent and application.
- Note third-party patents you know about and any freedom-to-operate work already done.
- Inventory trade secrets, data, software and materials, and who has access.
- Write down open issues honestly, with a plan to fix each one.
Perspective
Most IP problems we see are not exotic. They are ordinary gaps: an assignment nobody signed, a license whose field is narrower than the business plan, a grant that was never mapped to an invention. They are cheap to fix early and expensive to fix under deadline.
Our team has worked inside major university technology transfer offices, in startup leadership, in federal grant review and in industry commercialization. That mix matters, because IP due diligence looks different depending on which chair you sit in. A university wants a clean path to a licensee. A founder wants a financeable company. An investor wants no surprises. We prepare clients for all three views.
Our advice is to treat diligence as part of commercialization strategy, not a legal chore at the end. The commercial case, the patent strategy and the license terms should be built together. Where legal opinions are needed, we coordinate with a dedicated IP law partner so the strategy and the legal work stay aligned.
the author
Get ready before the counterparty asks
If you are a university, researcher or founder heading into a license, spinout or financing, we can help you organize your IP position, tighten your licensing and patent strategy, and prepare the story investors and licensees will want to hear. Our services cover IP and patent strategy, licensing, spinout formation, life sciences and device commercialization, funding strategy and market assessments. See our consulting services to find the right starting point.

If your product is a medical device or drug, regulatory planning belongs in the same conversation. Our guide to medical device regulatory strategy shows how the pieces connect.
FAQ
How long does IP due diligence take?
It depends on the number of assets, the quality of your records and the depth the deal requires. A small startup with a tidy IP map can be reviewed quickly, while a portfolio with many licenses and sponsored agreements takes longer. Preparing documents in advance is the biggest time saver.
What is the difference between IP due diligence and a freedom-to-operate analysis?
Due diligence is the broad review of ownership, strength, restrictions and risk. Freedom to operate is one part of it, focused on whether your product infringes someone else's rights. You can own strong patents and still need a license from a third party.
Who should run biotech IP due diligence?
It works best as a team effort. Scientists explain what the technology does, commercial advisors test whether the rights fit the business plan, and IP counsel gives legal opinions on validity, infringement and contracts. Federal funding and university terms need specific attention.
What are the most common red flags for a startup?
Unsigned invention assignments, university or sponsor rights nobody documented, licenses with a field narrower than the plan, unpaid maintenance fees and unmapped government funding. Most are fixable if found early, which is the reason to review your own IP first.
Do I need it if I am only licensing a university technology?
Yes, in proportion to the stakes. Confirm who owns the technology, what funding supported it, what rights the government holds and whether the field, territory and exclusivity match your plan. Then check freedom to operate for your product.
Sources
- IP Due Diligence: Everything You Need To Know (Association of Corporate Counsel)
- IP Due Diligence Readiness (WIPO)
- Preparing for IP Diligence
- The Founder's Guide to University Licensing (Nucleate)
- IP Due Diligence Issues in M&A Transactions
- Life Sciences Quarterly: What IP Diligence is Due
- Pocket guide to bio and pharma IP due diligence
- PSU Inventor's Guide to Tech Transfer
- The Bayh-Dole Act: A Guide to the Law and Implementing Regulations (COGR)
- The Technology Transfer Office: Inventor's Guidebook (Case Western Reserve University)
